PH12022551081A1 - Cancer treatments targeting cancer stem cells - Google Patents
Cancer treatments targeting cancer stem cellsInfo
- Publication number
- PH12022551081A1 PH12022551081A1 PH1/2022/551081A PH12022551081A PH12022551081A1 PH 12022551081 A1 PH12022551081 A1 PH 12022551081A1 PH 12022551081 A PH12022551081 A PH 12022551081A PH 12022551081 A1 PH12022551081 A1 PH 12022551081A1
- Authority
- PH
- Philippines
- Prior art keywords
- cancer
- compounds
- stem cells
- kits
- compositions
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 6
- 201000011510 cancer Diseases 0.000 title abstract 6
- 210000000130 stem cell Anatomy 0.000 title abstract 2
- 230000008685 targeting Effects 0.000 title abstract 2
- 238000011282 treatment Methods 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 206010006187 Breast cancer Diseases 0.000 abstract 1
- 208000026310 Breast neoplasm Diseases 0.000 abstract 1
- 206010009944 Colon cancer Diseases 0.000 abstract 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 abstract 1
- 206010014733 Endometrial cancer Diseases 0.000 abstract 1
- 206010014759 Endometrial neoplasm Diseases 0.000 abstract 1
- 206010051066 Gastrointestinal stromal tumour Diseases 0.000 abstract 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 abstract 1
- 206010025323 Lymphomas Diseases 0.000 abstract 1
- 208000034578 Multiple myelomas Diseases 0.000 abstract 1
- 206010033128 Ovarian cancer Diseases 0.000 abstract 1
- 206010061535 Ovarian neoplasm Diseases 0.000 abstract 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 abstract 1
- 206010035226 Plasma cell myeloma Diseases 0.000 abstract 1
- 206010060862 Prostate cancer Diseases 0.000 abstract 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 abstract 1
- 208000005718 Stomach Neoplasms Diseases 0.000 abstract 1
- 208000024313 Testicular Neoplasms Diseases 0.000 abstract 1
- 206010057644 Testis cancer Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 206010017758 gastric cancer Diseases 0.000 abstract 1
- 201000011243 gastrointestinal stromal tumor Diseases 0.000 abstract 1
- 208000032839 leukemia Diseases 0.000 abstract 1
- 201000007270 liver cancer Diseases 0.000 abstract 1
- 208000014018 liver neoplasm Diseases 0.000 abstract 1
- 201000005202 lung cancer Diseases 0.000 abstract 1
- 208000020816 lung neoplasm Diseases 0.000 abstract 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 abstract 1
- 201000002528 pancreatic cancer Diseases 0.000 abstract 1
- 208000008443 pancreatic carcinoma Diseases 0.000 abstract 1
- 230000001172 regenerating effect Effects 0.000 abstract 1
- 201000011549 stomach cancer Diseases 0.000 abstract 1
- 201000003120 testicular cancer Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Enzymes And Modification Thereof (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962931531P | 2019-11-06 | 2019-11-06 | |
| PCT/US2020/059329 WO2021092322A1 (en) | 2019-11-06 | 2020-11-06 | Cancer treatments targeting cancer stem cells |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PH12022551081A1 true PH12022551081A1 (en) | 2024-06-19 |
Family
ID=73643356
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PH1/2022/551081A PH12022551081A1 (en) | 2019-11-06 | 2020-11-06 | Cancer treatments targeting cancer stem cells |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US12612368B2 (https=) |
| EP (1) | EP4055008A1 (https=) |
| JP (2) | JP7690470B2 (https=) |
| KR (1) | KR20220110744A (https=) |
| CN (2) | CN119930509A (https=) |
| AU (1) | AU2020378067A1 (https=) |
| BR (1) | BR112022008753A2 (https=) |
| CA (1) | CA3157315A1 (https=) |
| CO (1) | CO2022007910A2 (https=) |
| IL (1) | IL292718A (https=) |
| MX (1) | MX2022005445A (https=) |
| PH (1) | PH12022551081A1 (https=) |
| WO (1) | WO2021092322A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12522587B2 (en) | 2018-05-04 | 2026-01-13 | Remedy Plan, Inc. | Cancer treatments targeting cancer stem cells |
| EP4055008A1 (en) | 2019-11-06 | 2022-09-14 | Remedy Plan, Inc. | Cancer treatments targeting cancer stem cells |
| JP2024518089A (ja) * | 2021-05-13 | 2024-04-24 | リメディー プラン，インコーポレーテッド | Ｎａｍｐｔ阻害剤とその使用 |
| CN119234351A (zh) | 2022-09-01 | 2024-12-31 | 株式会社Lg新能源 | 二次电池和包括该二次电池的装置 |
| CN116139141A (zh) * | 2022-12-14 | 2023-05-23 | 复旦大学 | Agk2促进肝癌的免疫治疗的用途 |
Family Cites Families (101)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4311698A (en) | 1979-03-12 | 1982-01-19 | Haskell Theodore H | Aminoacid derivatives of cephalosporin compounds |
| US4278681A (en) | 1979-03-12 | 1981-07-14 | Warner-Lambert Co. | Antibacterial amide compounds and means for using the same |
| JPS56115784A (en) | 1980-02-15 | 1981-09-11 | Tanabe Seiyaku Co Ltd | Novel pyridinecarboxamide derivative and its preparation |
| US4315014A (en) | 1980-09-24 | 1982-02-09 | Warner-Lambert Company | Antibacterial amide compounds and pharmaceutical composition containing the same |
| US4315858A (en) | 1980-09-24 | 1982-02-16 | Warner-Lambert Company | Antibacterial amide compounds |
| JPH02127512A (ja) | 1988-11-07 | 1990-05-16 | Motoo Takayanagi | ピラジン環含有芳香族ポリアミド繊維 |
| JPH02127429A (ja) | 1988-11-07 | 1990-05-16 | Motoo Takayanagi | ピラジン環含有芳香族ポリアミドおよびその製造法 |
| GB2273930A (en) | 1992-12-30 | 1994-07-06 | Glaxo Group Ltd | Benzanilide derivatives |
| US5563143A (en) | 1994-09-21 | 1996-10-08 | Pfizer Inc. | Catechol diether compounds as inhibitors of TNF release |
| DE19624659A1 (de) | 1996-06-20 | 1998-01-08 | Klinge Co Chem Pharm Fab | Neue Pyridylalken- und Pyridylalkinsäureamide |
| DE19624668A1 (de) | 1996-06-20 | 1998-02-19 | Klinge Co Chem Pharm Fab | Verwendung von Pyridylalkan-, Pyridylalken- bzw. Pyridylalkinsäureamiden |
| JP3354090B2 (ja) | 1996-09-30 | 2002-12-09 | シエーリング アクチエンゲゼルシャフト | 分化誘導剤 |
| JP4405602B2 (ja) | 1998-04-16 | 2010-01-27 | バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト | ヒストン脱アセチル化酵素阻害剤 |
| JP2000256194A (ja) | 1999-01-06 | 2000-09-19 | Mitsui Chemicals Inc | 核内レセプタ作動薬およびその効果増強剤 |
| AU7278500A (en) | 1999-08-18 | 2001-03-13 | Aventis Cropscience Gmbh | Fungicides |
| EE200300360A (et) | 2001-01-31 | 2003-12-15 | Pfizer Products Inc. | PDE4 isosüümide inhibiitoritena kasutatavad nikotiinamiidi biarüülderivaadid |
| WO2003003008A1 (en) | 2001-06-29 | 2003-01-09 | 7Tm Pharma A/S | Chemical libraries useful for drug discovery processes |
| WO2003003009A1 (en) | 2001-06-29 | 2003-01-09 | 7Tm Pharma A/S | Use of metal-ion chelates in validating biological molecules as drug targets in test animal models |
| WO2003055477A1 (en) | 2001-12-21 | 2003-07-10 | 7Tm Pharma A/S | Method for the treatment of mc receptor related disorders with a chelate and/or a chelator |
| JP4505228B2 (ja) | 2002-01-10 | 2010-07-21 | バイエル・シェーリング・ファルマ・アクチェンゲゼルシャフト | Ｒｈｏ−キナーゼ阻害剤 |
| EP1348434A1 (en) | 2002-03-27 | 2003-10-01 | Fujisawa Deutschland GmbH | Use of pyridyl amides as inhibitors of angiogenesis |
| EP1738752A1 (en) | 2002-12-27 | 2007-01-03 | Schering Aktiengesellschaft | Pharmaceutical combinations comprising cis-retine acid |
| DE10334724A1 (de) | 2003-07-30 | 2005-02-24 | Bayer Healthcare Ag | N-Biarylamide |
| JP2008510726A (ja) | 2004-08-20 | 2008-04-10 | エントレメッド インコーポレイテッド | プロテイナーゼ活性化受容体アンタゴニストを含む組成物および方法 |
| ES2377430T3 (es) | 2004-09-02 | 2012-03-27 | Genentech, Inc. | Inhibidores piridílicos de la señalización de hedgehog |
| CN101128454A (zh) | 2004-12-22 | 2008-02-20 | 阿斯利康(瑞典)有限公司 | 用作抗癌药物的吡啶羧酰胺衍生物 |
| WO2006067445A2 (en) | 2004-12-22 | 2006-06-29 | Astrazeneca Ab | Csf-1r kinase inhibitors |
| GB0500828D0 (en) | 2005-01-15 | 2005-02-23 | Astrazeneca Ab | Benzamide derivatives |
| GB0501146D0 (en) | 2005-01-20 | 2005-02-23 | Astrazeneca Ab | Novel benzamide derivatives |
| JP2008545744A (ja) | 2005-06-02 | 2008-12-18 | バイエル・クロツプサイエンス・アクチエンゲゼルシヤフト | フェニルアルキル置換ヘテロアリール誘導体 |
| GB0514684D0 (en) | 2005-07-18 | 2005-08-24 | Novartis Ag | Organic compounds |
| BRPI0615133A2 (pt) | 2005-08-23 | 2011-05-03 | Irm Llc | compostos imunossupressores, composições farmacêuticas contendo os mesmos assim como referido uso |
| CA2630639A1 (en) | 2005-11-21 | 2007-05-31 | Tap Pharmaceutical Products, Inc. | Treatment of qt interval prolongation and diseases associated therewith |
| TWI372752B (en) | 2005-12-22 | 2012-09-21 | Nihon Nohyaku Co Ltd | Pyrazinecarboxamide derivatives and plant disease controlling agents containing the same |
| WO2007076055A2 (en) | 2005-12-22 | 2007-07-05 | Entremed, Inc. | Compositions and methods comprising proteinase activated receptor antagonists |
| AU2006336504C9 (en) | 2005-12-28 | 2015-05-14 | Vertex Pharmaceuticals Incorporated | 1-(benzo [D] [1,3] dioxol-5-yl) -N- (phenyl) cyclopropane- carboxamide derivatives and related compounds as modulators of ATP-Binding Cassette transporters for the treatment of Cystic Fibrosis |
| JP2009534458A (ja) | 2006-04-26 | 2009-09-24 | キャンサー・リサーチ・テクノロジー・リミテッド | アミノ−エチル−アミノ−アリール（ａｅａａ）化合物およびそれらの使用 |
| WO2008016643A2 (en) | 2006-08-01 | 2008-02-07 | Cytokinetics, Incorporated | Certain chemical entities, compositions, and methods |
| FR2904827B1 (fr) | 2006-08-11 | 2008-09-19 | Sanofi Aventis Sa | Derives de 5,6-bisaryl-2-pyridine-carboxamide, leur preparation et leur application en therapeutique comme antiganistes des recepteurs a l'urotensine ii |
| WO2008024963A1 (en) | 2006-08-24 | 2008-02-28 | Serenex, Inc. | Benzene, pyridine, and pyridazine derivatives |
| WO2008026018A1 (en) | 2006-09-01 | 2008-03-06 | Topotarget Switzerland Sa | New method for the treatment of inflammatory diseases |
| FR2921657A1 (fr) | 2007-09-28 | 2009-04-03 | Sanofi Aventis Sa | Derives de nicotinamide, leur preparation et leur application en therapeutique |
| US8324226B2 (en) | 2007-10-24 | 2012-12-04 | Cancer Research Technology Limited | Therapeutic oxy-phenyl-aryl compounds and their use |
| CA2705848C (en) | 2007-11-21 | 2016-02-02 | Bio-Rad Laboratories, Inc. | Photoluminescent metal complexes for protein staining |
| EP2639224B1 (en) | 2007-12-07 | 2016-08-24 | Vertex Pharmaceuticals Incorporated | Process for producing cycloalkylcarboxiamido-pyridine benzoic acids |
| US20100036130A1 (en) | 2007-12-07 | 2010-02-11 | Vertex Pharmaceuticals Incorporated | Processes for producing cycloalkylcarboxamido-pyridine benzoic acids |
| EP2098231A1 (en) | 2008-03-05 | 2009-09-09 | Topotarget Switzerland SA | Use of NAD formation inhibitors for the treatment of ischemia-reperfusion injury |
| US20090281089A1 (en) | 2008-04-11 | 2009-11-12 | Genentech, Inc. | Pyridyl inhibitors of hedgehog signalling |
| RU2011121655A (ru) | 2008-10-29 | 2012-12-10 | Сертрис Фармасьютикалз, Инк. | Производные пиридина, бициклические производные пиридина и родственные аналоги в качестве модуляторов сиртуина |
| US20110098311A1 (en) | 2009-10-22 | 2011-04-28 | Vertex Pharmaceuticals Incorported | Compositions for treatment of cystic fibrosis and other chronic diseases |
| US20130109682A1 (en) | 2010-07-06 | 2013-05-02 | Novartis Ag | Cyclic ether compounds useful as kinase inhibitors |
| WO2012054110A2 (en) | 2010-07-07 | 2012-04-26 | Ardelyx, Inc. | Compounds and methods for inhibiting phosphate transport |
| EP2591354B1 (en) | 2010-07-07 | 2016-09-07 | Ardelyx, Inc. | Compounds and methods for inhibiting phosphate transport |
| DK2599771T3 (en) | 2010-07-30 | 2016-10-24 | Daito Chemix Corp | naphthalene |
| WO2012024179A1 (en) | 2010-08-18 | 2012-02-23 | Merck Sharp & Dohme Corp. | Substituted amide derivatives as dgat-1 inhibitors |
| EP2611804A1 (en) | 2010-09-03 | 2013-07-10 | Forma TM, LLC. | Novel compounds and compositions for the inhibition of nampt |
| JP5822840B2 (ja) | 2010-09-30 | 2015-11-24 | ダイトーケミックス株式会社 | 眼疾患処置薬 |
| GB201106750D0 (en) | 2011-04-21 | 2011-06-01 | Glaxosmithkline Llc | Novel compounds |
| CA2836338C (en) | 2011-05-16 | 2022-05-03 | Koninklijke Philips N.V. | Tetrazine derivatives used in bio-orthogonal drug activation |
| WO2012158784A2 (en) | 2011-05-16 | 2012-11-22 | Theodore Mark Kamenecka | Modulators of the nuclear hormone receptor ror |
| EP2739144A4 (en) | 2011-06-20 | 2015-04-01 | Alzheimer S Inst Of America Inc | COMPOUNDS AND ITS THERAPEUTIC USE |
| WO2013028445A1 (en) | 2011-08-19 | 2013-02-28 | Glaxosmithkline Llc | Fatty acid synthase inhibitors |
| EP2589292A1 (en) | 2011-11-02 | 2013-05-08 | Bayer CropScience AG | Compounds with nematicidal activity |
| EP2773203A1 (en) | 2011-11-02 | 2014-09-10 | Bayer Intellectual Property GmbH | Compounds with nematicidal activity |
| GB201120993D0 (en) | 2011-12-06 | 2012-01-18 | Imp Innovations Ltd | Novel compounds and their use in therapy |
| CA2872652A1 (en) | 2012-05-07 | 2013-11-14 | The General Hospital Corporation | Novel compositions and uses of anti-hypertension agents for cancer therapy |
| AR091654A1 (es) | 2012-07-02 | 2015-02-18 | Biogen Idec Inc | COMPUESTOS QUE CONTIENEN BIARILO COMO AGONISTAS INVERSOS DE RECEPTORES ROR-g |
| WO2014081300A1 (en) | 2012-11-22 | 2014-05-30 | Tagworks Pharmaceuticals B.V. | Channel protein activatable liposomes |
| WO2014081299A1 (en) | 2012-11-22 | 2014-05-30 | Tagworks Pharmaceuticals B.V. | Activatable liposomes |
| FI2922574T3 (fi) | 2012-11-22 | 2023-08-11 | Tagworks Pharmaceuticals B V | Kemiallisesti pilkkoutuva ryhmä |
| US20150297741A1 (en) | 2012-11-22 | 2015-10-22 | Tagworks Pharmaceuticals B.V. | Bio-orthogonal drug activation |
| JP5799117B2 (ja) | 2013-02-05 | 2015-10-21 | 大日本住友製薬株式会社 | ウラシル誘導体からなる医薬 |
| WO2014145873A2 (en) | 2013-03-15 | 2014-09-18 | Epigen Biosciences, Inc. | Heterocyclic compounds useful in the treatment of disease |
| US20160046616A1 (en) | 2013-03-15 | 2016-02-18 | The Johns Hopkins University | Nrf2 small molecule inhibitors for cancer therapy |
| WO2014169073A1 (en) | 2013-04-09 | 2014-10-16 | Massachusetts Institute Of Technology | Drug delivery polymer and uses thereof |
| WO2014203217A1 (en) | 2013-06-21 | 2014-12-24 | Lupin Limited | Substituted heterocyclic compounds as crac modulators |
| GB201316823D0 (en) | 2013-09-23 | 2013-11-06 | R & D Vernalis Ltd | New Chemical Entities |
| CN105916500A (zh) | 2013-11-27 | 2016-08-31 | 欧洲筛选有限公司 | 用于治疗炎性疾病的化合物、药物组合物和方法 |
| EP3099677A4 (en) | 2014-01-31 | 2017-07-26 | Dana-Farber Cancer Institute, Inc. | Diaminopyrimidine benzenesulfone derivatives and uses thereof |
| HUE051255T2 (hu) | 2014-02-19 | 2021-03-01 | Aviv Therapeutics Inc | Mitokondriális aldehid dehidrogenáz 2 (ALDH2) kötõ policiklusos amidok és alkalmazásuk rák kezelésére |
| KR102265277B1 (ko) | 2014-04-11 | 2021-06-16 | 판옵테스 파르마 게스.엠.베.하. | 바이러스 억제 화합물로서의 항-염증제 |
| TW201625641A (zh) | 2014-05-22 | 2016-07-16 | 健臻公司 | Ｎａｍｐｔ抑制劑及方法 |
| WO2017009650A1 (en) | 2015-07-14 | 2017-01-19 | Mission Therapeutics Limited | Cyanopyrrolidines as dub inhibitors for the treatment of cancer |
| WO2017106436A1 (en) | 2015-12-15 | 2017-06-22 | University Of Miami | Inhibitors of tnf superfamily costimulatory interactions and methods for uses of the same |
| GB201602854D0 (en) | 2016-02-18 | 2016-04-06 | Mission Therapeutics Ltd | Novel compounds |
| CN108713013B (zh) | 2016-02-29 | 2021-06-18 | 住友化学株式会社 | 杂环化合物 |
| WO2017160116A2 (ko) | 2016-03-17 | 2017-09-21 | 연세대학교 산학협력단 | 니코틴아미드 포스포리보실트랜스퍼라제 억제용 신규 화합물 및 이를 포함하는 조성물 |
| WO2018017589A1 (en) | 2016-07-19 | 2018-01-25 | The General Hospital Corporation | Compounds for targeting cancer stem cells |
| US10398783B2 (en) | 2016-10-20 | 2019-09-03 | Bristol-Myers Squibb Company | Antiproliferative compounds and conjugates made therefrom |
| WO2018101424A1 (ja) | 2016-12-01 | 2018-06-07 | 住友化学株式会社 | 複素環化合物及びそれを含有する有害節足動物防除組成物 |
| CN108314677B (zh) | 2017-01-17 | 2020-06-30 | 安徽中科拓苒药物科学研究有限公司 | 一种ezh2抑制剂及其用途 |
| BR112019021388B1 (pt) | 2017-04-11 | 2023-10-31 | Mitsui Chemicals Crop & Life Solutions, Inc | Compostos, agente de controle de pragas agrícolas e hortícolas, fungicida agrícola e hortícola e métodos para prevenção e/ou tratamento de uma doença de plantas |
| RS65914B1 (sr) | 2017-04-18 | 2024-10-31 | Lilly Co Eli | Fenil-2-hidroksi-acetilamino-2-metil-fenil jedinjenja |
| JP7211358B2 (ja) | 2017-05-22 | 2023-01-24 | 小野薬品工業株式会社 | Ｅｐ４アンタゴニスト |
| EP3746070A4 (en) | 2018-01-29 | 2021-09-01 | Capulus Therapeutics, LLC | SREBP INHIBITORS WITH A 6-LINKED CENTER RING |
| US12522587B2 (en) | 2018-05-04 | 2026-01-13 | Remedy Plan, Inc. | Cancer treatments targeting cancer stem cells |
| JP7399589B2 (ja) | 2018-09-12 | 2023-12-18 | 日本化薬株式会社 | 有害生物防除剤 |
| EP4055008A1 (en) | 2019-11-06 | 2022-09-14 | Remedy Plan, Inc. | Cancer treatments targeting cancer stem cells |
| KR102210267B1 (ko) | 2020-05-26 | 2021-02-01 | (주)피엔에이치테크 | 유기발광 화합물 및 이를 포함하는 유기발광소자 |
| KR20230061442A (ko) | 2020-09-02 | 2023-05-08 | 도꾜 다이가꾸 | 유기 반도체 재료 |
| JP2024518089A (ja) | 2021-05-13 | 2024-04-24 | リメディー プラン，インコーポレーテッド | Ｎａｍｐｔ阻害剤とその使用 |
-
2020
- 2020-11-06 EP EP20816347.7A patent/EP4055008A1/en active Pending
- 2020-11-06 CN CN202510009927.XA patent/CN119930509A/zh active Pending
- 2020-11-06 CA CA3157315A patent/CA3157315A1/en active Pending
- 2020-11-06 BR BR112022008753A patent/BR112022008753A2/pt unknown
- 2020-11-06 MX MX2022005445A patent/MX2022005445A/es unknown
- 2020-11-06 CN CN202080091217.1A patent/CN114929672B/zh active Active
- 2020-11-06 PH PH1/2022/551081A patent/PH12022551081A1/en unknown
- 2020-11-06 JP JP2022526226A patent/JP7690470B2/ja active Active
- 2020-11-06 KR KR1020227018395A patent/KR20220110744A/ko active Pending
- 2020-11-06 US US17/774,583 patent/US12612368B2/en active Active
- 2020-11-06 AU AU2020378067A patent/AU2020378067A1/en active Pending
- 2020-11-06 WO PCT/US2020/059329 patent/WO2021092322A1/en not_active Ceased
-
2022
- 2022-05-03 IL IL292718A patent/IL292718A/en unknown
- 2022-06-03 CO CONC2022/0007910A patent/CO2022007910A2/es unknown
-
2025
- 2025-05-29 JP JP2025089886A patent/JP2025143254A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2022553865A (ja) | 2022-12-26 |
| CN119930509A (zh) | 2025-05-06 |
| AU2020378067A1 (en) | 2022-05-26 |
| CA3157315A1 (en) | 2021-05-14 |
| EP4055008A1 (en) | 2022-09-14 |
| WO2021092322A1 (en) | 2021-05-14 |
| BR112022008753A2 (pt) | 2022-07-19 |
| JP7690470B2 (ja) | 2025-06-10 |
| KR20220110744A (ko) | 2022-08-09 |
| IL292718A (en) | 2022-07-01 |
| JP2025143254A (ja) | 2025-10-01 |
| CN114929672A (zh) | 2022-08-19 |
| CO2022007910A2 (es) | 2022-08-19 |
| CN114929672B (zh) | 2025-01-21 |
| MX2022005445A (es) | 2022-08-10 |
| US20230023124A1 (en) | 2023-01-26 |
| US12612368B2 (en) | 2026-04-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12022551081A1 (en) | Cancer treatments targeting cancer stem cells | |
| PH12022551013A1 (en) | Pyridazinones as parp7 inhibitors | |
| PH12022550892A1 (en) | Bicyclic heterocycles as fgfr inhibitors | |
| PH12018500587A1 (en) | Pyrazolopyrimidine derivatives as btk inhibitors for the treatment of cancer | |
| EP4552631A3 (en) | Combination of dasatinib and adagrasib for use in the treatment of non-small cell lung cancer | |
| MY183036A (en) | Amino-triazolopyridine compounds and their use in treating cancer | |
| MY200590A (en) | Compounds useful as kinase inhibitors | |
| WO2016161410A3 (en) | Treatment of cancer using inhibitors of tgf-beta and pd-1 | |
| MY196836A (en) | Spiro-condensed pyrrolidine derivatives as deubiquitylating enzymes (dub) inhibitors | |
| EA201991622A1 (ru) | Комплексная терапия для лечения рака | |
| MX2022000310A (es) | Inhibidores de proteina bcl-2. | |
| MX2024013215A (es) | Compuestos para inhibir kif18a | |
| MX2020012291A (es) | Compuestos para el tratamiento de cancer de mama triple negativo y cancer de ovario. | |
| PH12021553132A1 (en) | Methods of using rad51 inhibitors for treatment of pancreatic cancer | |
| WO2020055643A3 (en) | Compounds, compositions and methods for treating or preventing her-driven cancers | |
| NZ726365A (en) | Combinations for treating cancers | |
| MX2020010437A (es) | Inhibidores de axl cinasa y uso de los mismos. | |
| MX2022008099A (es) | Tratamiento para el cancer con inhibidores de cdk12/13. | |
| MX2021011524A (es) | Inhibidores de proteina arginina n-metiltransferasa 5 (prmt5) y usos de los mismos. | |
| MX2025001802A (es) | Moduladores de rbm39 heterociclicos | |
| WO2024006292A3 (en) | Methods of treating cancer | |
| MX2021008834A (es) | Metodos de tratamiento del cancer de mama con tucatinib. | |
| EP4431598A3 (en) | Compositions and methods for enhancing production, growth, spread, or oncolytic and immunotherapeutic efficacy of interferon-sensitive viruses | |
| PH12021551657A1 (en) | Anti-androgens for the treatment of metastatic castration-sensitive prostate cancer | |
| NZ779815A (en) | Indazolyl-isoxazole derivatives for the treatment of diseases such as cancer |